Download PDF
Aktuelle Rheumatologie 2017; 42(04): 301-309
DOI: 10.1055/s-0042-118384
Übersichtsarbeit
© Georg Thieme Verlag KG Stuttgart · New York

Systemische Sklerose

Systemic Sclerosis
G. Riemekasten
1   Klinik für Rheumatologie, Universität zu Lübeck, Lübeck
,
S. Schinke
1   Klinik für Rheumatologie, Universität zu Lübeck, Lübeck
› Author Affiliations
Further Information

Publication History

Publication Date:
30 August 2017 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die systemische Sklerose gehört zu den rheumatischen Erkrankungen mit dem höchsten Einfluss auf die Prognose und Lebensqualität. Organmanifestationen wie die interstitielle Lungenfibrose, die pulmonale arterielle Hypertonie (PAH) und die Herzbeteiligung bestimmen die Mortalität, während Schmerzen, Bewegungseinschränkungen und digitale Ulzerationen häufig die Lebensqualität beeinflussen. Mangelernährung, Sarkopenie, Depression, Osteoporose, kardiovaskuläre Erkrankungen und Tumorerkrankungen treten möglicherweise bedingt durch die chronische Aktivierung des Immunsystems gehäuft auf. Es gibt derzeit erste Ansätze, Krankheitsmechanismen und die Beziehung zwischen der obliterativen Vaskulopathie und der variabel vorhandenen Fibrose zu verstehen. Die Therapie sollte frühzeitig beginnen. Eine Reihe von Substanzen beeinflusst die Raynaud-Symptomatik und die obliterative Gefäßerkrankung. Leider werden diese Therapien oftmals nicht ausreichend genutzt. Immunsuppressiva wie Cyclophosphamid, MMF oder eine autologe Stammzelltransplantation haben zu einer deutlichen Verbesserung der inflammatorischen Fibrose in klinischen Studien geführt. Neue Therapieansätze, die Krankheitsmechanismen beeinflussen und nebenwirkungsärmer sind, erscheinen erfolgversprechend und könnten künftig zu einer Zulassung führen. Derzeit wird eine Vielzahl von Studien durchgeführt. Die konsequente zielorientierte und individuelle Therapie stellt einen wichtigen Schlüssel zum Therapieerfolg dar.

Abstract

Systemic sclerosis is one of the most severe rheumatic diseases with a strong impact on quality of life and prognosis. Interstitial lung disease, pulmonary arterial hypertension (PAH) and cardiac manifestations are the most important reasons for death. Pain, loss of range of motion, and digital ulcers often determine quality of life. There is a high prevalence of malnutrition, sarcopenia, depression, osteoporosis, cardiovascular events, and malignancies. Chronic activation of the immune system might contribute to the increased rate of these co-morbidities. We have some initial approaches to understand the mechanisms of the disease and the link between obliterative vasculopathy and the variable existence of fibrosis. Treatment should start early. Several drugs have shown efficacy to improve Raynaud’s phenomenon and obliterative vasculopathy. Unfortunately, they are often used inconsistently. Treatments such as cyclophosphamide, mycophenolate mofetil, or autologous stem cell transplantation have shown to improve inflammatory fibrosis in clinical studies of systemic sclerosis. New drugs targeting key mechanisms could provide novel approaches with fewer side effects. Several studies are ongoing. Consistent individual and target-oriented therapies are the key to a successful treatment of patients with systemic sclerosis.

Schlüsselwörter

Systemische Sklerose - Lungenfibrose - Autoantikörper - vasoaktive Therapie - Biologika

Key words

systemic sclerosis - vasoactive therapy - autoantibody - biologicals - pulmonary fibrosis
 

  • Literatur

  • 1 Sunderkötter C, Riemekasten G. Raynaud phenomenon in dermatology. Part 1: Pathophysiology and diagnostic approach. Hautarzt 2006; 57: 819-828 quiz 829. Review
    CrossrefPubMedGoogle Scholar
  • 2 Koenig M, Joyal F, Fritzler MJ. et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum. 2008; 58: 3902-3912
    CrossrefPubMedGoogle Scholar
  • 3 Riemekasten G, Krieg T, Guillevin L et al.Matucci-Cerinic M on behalf of the DUO Registry Investigators. Treatment pattern of digital ulcers in various European countries – Findings from the DUO Registry. Abstract DGRh 2012
    PubMed
  • 4 Van den Hoogen F, Khanna D, Fransen J. et al. 2013; classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013; 65: 2737-2747
    CrossrefPubMedGoogle Scholar
  • 5 Andréasson K, Saxne T, Bergknut C. et al. Prevalence and incidence of systemic sclerosis in southern Sweden: population-based data with case ascertainment using the 1980 ARA criteria and the proposed ACR-EULAR classification criteria. Ann Rheum Dis. 2014; 73: 1788-1792
    CrossrefPubMedGoogle Scholar
  • 6 Furst DE, Clements PJ, Steen VD. et al. The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol. 1998; 25: 84-88
    PubMedGoogle Scholar
  • 7 LeRoy EC, Black C, Fleischmajer R. et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-205
    PubMedGoogle Scholar
  • 8 Hanitsch LG, Burmester GR, Witt C et al. Skin sclerosis is only of limited value to identify SSc patients with severe manifestations – an analysis of a distinct patient subgroup of the German Systemic Sclerosis Network (DNSS) Register.
    PubMed
  • 9 Hanke K, Becker MO, Brueckner CS. et al. Anticentromere-A and anticentromere-B antibodies show high concordance and similar clinical associations in patients with systemic sclerosis. J Rheumatol 2010; 37: 2548-2552
    CrossrefPubMedGoogle Scholar
  • 10 Hanke K, Dähnrich C, Brückner CS. et al. Diagnostic value of anti-topoisomerase I antibodies in a large monocentric cohort. Arthritis Res Ther 2009; 11: R28
    CrossrefPubMedGoogle Scholar
  • 11 Onishi A, Sugiyama D, Kumagai S. et al. Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies. Arthritis Rheum 2013; 65: 1913-1921
    CrossrefPubMedGoogle Scholar
  • 12 Tyndall A, Fistarol S. The differential diagnosis of systemic sclerosis. Curr Opin Rheumatol 2013; 25: 692-699
    CrossrefPubMedGoogle Scholar
  • 13 Riemekasten G, Philippe A, Näther M. et al. Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. Ann Rheum Dis 2011; 70: 530-536
    CrossrefPubMedGoogle Scholar
  • 14 Kill A, Tabeling C, Undeutsch R. et al. Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis. Arthritis Res Ther 2014; 16: R29
    CrossrefPubMedGoogle Scholar
  • 15 Becker MO, Kill A, Kutsche M. et al. Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis. Am J Respir Crit Care Med 2014; 190: 808-817
    CrossrefPubMedGoogle Scholar
  • 16 Günther J, Kill A, Becker MO. et al. Angiotensin receptor type 1 and endothelin receptor type A on immune cells mediate migration and the expression of IL-8 and CCL18 when stimulated by autoantibodies from systemic sclerosis patients. Arthritis Res Ther 2014; 16: R65
    CrossrefPubMedGoogle Scholar
  • 17 Kill A, Riemekasten G. Functional autoantibodies in systemic sclerosis pathogenesis. Curr Rheumatol Rep 2015; 17: 34
    CrossrefPubMedGoogle Scholar
  • 18 Kill A, Tabeling C, Undeutsch R. et al. Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis. Arthritis Res Ther 2014; 16: R29 10
    CrossrefPubMedGoogle Scholar
  • 19 Cabral-Marques O, Riemekasten G. Vascular hypothesis revisited: Role of stimulating antibodies against angiotensin and endothelin receptors in the pathogenesis of systemic sclerosis. Autoimmun Rev 2016 pii: S1568-9972(16)30053-2
    PubMed
  • 20 Günther J, Rademacher J, van Laar JM. et al. Functional autoantibodies in systemic sclerosis. Semin Immunopathol 2015; 37: 529-542
    CrossrefPubMedGoogle Scholar
  • 21 Rademacher J, Kill A, Mattat K. et al. Angiotensin and endothelin receptor imbalance modulate secretion of the profibrotic chemokine ligand 18. J Rheumatol 2016; 43: 587-591
    CrossrefPubMedGoogle Scholar
  • 22 Sulli A, Soldano S, Pizzorni C. et al. Raynaud's phenomenon and plasma endothelin: correlations with capillaroscopic patterns in systemic sclerosis. J Rheumatol. 2009; 36: 1235-1239
    CrossrefPubMedGoogle Scholar
  • 23 Kawaguchi Y, Takagi K, Hara M. et al. Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type 1 receptors. Arthritis Rheum 2004; 50: 216-226
    CrossrefPubMedGoogle Scholar
  • 24 van Laar JM, Farge D, Sont JK. et al. Autologous hematopoietic stem cell transplantation vs. intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 2014; 311: 2490-2498
    CrossrefPubMedGoogle Scholar
  • 25 Tashkin DP, Elashoff R, Clements PJ. et al. Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006; 354: 2655-2666
    CrossrefPubMedGoogle Scholar
  • 26 Iudici M, Cuomo G, Vettori S. et al. Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): efficacy of maintenance immunosuppression in responders and non-responders. Semin Arthritis Rheum 2015; 44: 437-444
    CrossrefPubMedGoogle Scholar
  • 27 Wirz EG, Jaeger VK, Allanore Y et al. Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database. Ann Rheum Dis 2015 Epub ahead of print
    PubMed
  • 28 Chung WS, Lin CL, Sung FC. et al. Systemic sclerosis increases the risks of deep vein thrombosis and pulmonary thromboembolism: a nationwide cohort study. Rheumatology (Oxford) 2014; 53: 1639-1645
    CrossrefPubMedGoogle Scholar
  • 29 Coghlan JG, Denton CP, Grünig E. et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis. 2014; 73: 1340-1349
    CrossrefPubMedGoogle Scholar
  • 30 Humbert M, Yaici A, de Groote P. et al. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Arthritis Rheum 2011; 63: 3522-3530
    CrossrefPubMedGoogle Scholar
  • 31 Tyndall AJ, Bannert B, Vonk M. et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69: 1809-1815
    CrossrefPubMedGoogle Scholar
  • 32 Willems LM, Vriezekolk JE, Schouffoer AA. et al. Effectiveness of nonpharmacologic interventions in systemic sclerosis: a systematic review. Arthritis Care Res (Hoboken) 2015; 67: 1426-1439
    CrossrefPubMedGoogle Scholar
  • 33 Marie I, Leroi AM, Gourcerol G. et al. Fructose Malabsorption in Systemic Sclerosis. Medicine (Baltimore) 2015; 94: e1601
    CrossrefPubMedGoogle Scholar
  • 34 Krause L, Becker MO, Brueckner CS. et al. Nutritional status as marker for disease activity and severity predicting mortality in patients with systemic sclerosis. Ann Rheum Dis 2010; 69: 1951-1957
    CrossrefPubMedGoogle Scholar
  • 35 Sunderkötter C, Riemekasten G. Raynaud phenomenon in dermatology: Part 2: therapy. Hautarzt 2006; 57: 927-938
    CrossrefPubMedGoogle Scholar
  • 36 Riemekasten G, Hoffmann U, Sunderkötter C. et al. Management of digital ulcers in patients with systemic sclerosis. Dtsch Med Wochenschr 2012; 137: 34-40
    Article in Thieme ConnectPubMedGoogle Scholar
  • 37 Hachulla E, Hatron PY, Carpentier P et al. SEDUCE study group. Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study. Ann Rheum Dis 2015 Epub ahead of print
    PubMed
  • 38 Kowal-Bielecka O, Landewé R, Avouac J. et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009; 68: 620-628
    CrossrefPubMedGoogle Scholar
  • 39 Bellando-Randone S, Lepri G, Bruni C. et al. Combination therapy with Bosentan and Sildenafil improves Raynaud's phenomenon and fosters the recovery of microvascular involvement in systemic sclerosis. Clin Rheumatol 2016; 35: 127-132
    CrossrefPubMedGoogle Scholar
  • 40 Pope JE, Bellamy N, Seibold JR. et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001; 44: 1351-1358
    CrossrefPubMedGoogle Scholar
  • 41 van den Hoogen FH, Boerbooms AM, Swaak AJ. et al. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 1996; 35: 364-372
    CrossrefPubMedGoogle Scholar
  • 42 Khanna D, Denton CP, Jahreis A et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet 2016 pii: S0140-6736(16)00232-4
    PubMed
  • 43 Nadashkevich O, Davis P, Fritzler M. et al. A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol 2006; 25: 205-212
    CrossrefPubMedGoogle Scholar
  • 44 Poormoghim H, Rezaei N, Sheidaie Z. et al. Systemic sclerosis: comparison of efficacy of oral cyclophosphamide and azathioprine on skin score and pulmonary involvement – a retrospective study. Rheumatol Int 2014; 34: 1691-1699
    CrossrefPubMedGoogle Scholar
  • 45 Takehara K, Ihn H, Sato S. A randomized, double-blind, placebo-controlled trial: intravenous immunoglobulin treatment in patients with diffuse cutaneous systemic sclerosis. Clin Exp Rheumatol 2013; 31 (Suppl. 76) 151-156
    PubMedGoogle Scholar
  • 46 de Paoli FV, Nielsen BD, Rasmussen F. et al. Abatacept induces clinical improvement in patients with severe systemic sclerosis. Scand J Rheumatol 2014; 43: 342-345
    CrossrefPubMedGoogle Scholar
  • 47 Khanna D, Denton CP, Jahreis A. et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet 2016; 387: 2630-2640
    CrossrefPubMedGoogle Scholar
  • 48 Moazedi-Fuerst FC, Kielhauser SM, Bodo K. et al. Dosage of rituximab in systemic sclerosis: 2-year results of five cases. Clin Exp Dermatol 2015; 40: 211-212
    CrossrefPubMedGoogle Scholar
  • 49 Filaci G, Cutolo M, Basso M. et al. Long-term treatment of patients affected by systemic sclerosis with cyclosporin A. Rheumatology (Oxford) 2001; 40: 1431-1432
    CrossrefPubMedGoogle Scholar
  • 50 Rice LM, Padilla CM, McLaughlin SR. et al. Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients. J Clin Invest 2015; 125: 2795-2807
    CrossrefPubMedGoogle Scholar